Caris uses the most advanced technologies for biomarker identification, allowing our medical teams to understand fully the biology of the tumor, which helps oncologists plan the best treatment strategy.

• Next-Generation Sequencing (NGS): Caris has one of the most advanced sequencing laboratories in the world, enabling Whole Exome (DNA) and Whole Transcriptome (RNA) sequencing on every patient.
  • DNA Sequencing: Whole Exome DNA sequencing is performed on all tumor types and for every patient, enabling accurate detection of mutations, copy number variations, insertions and deletions in a large number of cancer-relevant genes, plus precisely characterize homologous recombination deficiency (HRD), genome-wide loss of heterozygosity (LOH), microsatellite instability (MSI), tumor mutational burden (TMB) and human leukocyte antigen (HLA) genotyping.
  • RNA Sequencing: Whole Transcriptome RNA Sequencing analysis is performed on every patient and is the superior method to detect clinically relevant aberrations such as gene-fusion events and splice variants. RNA provides sequence information after gene splicing has occurred, thus avoiding the complexities of genomic features of DNA, such as large intronic regions. Caris molecular profiling has the ability to detect rare fusion events far better than DNA-based short-read methods, and provides broad coverage of all exons, capturing all possible fusion partners.
• Immunohistochemistry (IHC): Caris evaluates protein biomarkers through an extensive immunohistochemical panel analyzed in a tumor-type specific manner to conserve tissue and avoid unnecessary testing. Our large team of board-certified expert pathologists utilizes digital pathology, overseeing application and interpretation of this technology.
• In situ Hybridization (ISH): For select genes, we offer ISH to provide higher level of resolution to our IHC results to detect amplification.
• Pyrosequencing (PyroSeq): We offer methylation analysis of the MGMT promoter to guide therapy selection in glioma.
• Microdissection: The Caris Pathology team reviews every sample prepared for DNA and RNA sequencing and performs microdissection on every specimen, which results in a significant enrichment of the sample for DNA and RNA derived from the tumor. Because of this process, we are able to provide results in more than 95% of the cases and are able to detect molecular sub-clones present in the tumor.